Trials missing primary endpoints is fairly common.
Post# of 148172
(Total Views: 431)
Posted On: 09/21/2021 12:44:06 AM
Trials missing primary endpoints is fairly common. Provided the data is promising, you adjust and try again.
I have been invested in a few biotechs. Not an expert by any means.
I have concerns as well about trial designs and unforseen challenges, but what I come back to is what the doctors using Leronlimab have said.
But, until we prove it out in trials it means nothing.
I have been invested in a few biotechs. Not an expert by any means.
I have concerns as well about trial designs and unforseen challenges, but what I come back to is what the doctors using Leronlimab have said.
But, until we prove it out in trials it means nothing.
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼